BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 34448684)

  • 1. MD simulation and MM/PBSA identifies phytochemicals as bifunctional inhibitors of SARS-CoV-2.
    Sharma M; Mahto JK; Dhaka P; Neetu N; Tomar S; Kumar P
    J Biomol Struct Dyn; 2022; 40(22):12048-12061. PubMed ID: 34448684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening of phytochemicals as potent inhibitor of 3-chymotrypsin and papain-like proteases of SARS-CoV2: an in silico approach to combat COVID-19.
    Swargiary A; Mahmud S; Saleh MA
    J Biomol Struct Dyn; 2022 Mar; 40(5):2067-2081. PubMed ID: 33089730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular docking and simulation studies of natural compounds of
    Mitra D; Verma D; Mahakur B; Kamboj A; Srivastava R; Gupta S; Pandey A; Arora B; Pant K; Panneerselvam P; Ghosh A; Barik DP; Mohapatra PKD
    J Biomol Struct Dyn; 2022 Aug; 40(12):5665-5686. PubMed ID: 33459176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
    Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
    J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of natural inhibitors against Mpro of SARS-CoV-2 by molecular docking, molecular dynamics simulation, and MM/PBSA methods.
    Sharma P; Joshi T; Mathpal S; Joshi T; Pundir H; Chandra S; Tamta S
    J Biomol Struct Dyn; 2022 Apr; 40(6):2757-2768. PubMed ID: 33143552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of phytoconstituents of
    Choudhary P; Singh T; Amod A; Singh S
    J Biomol Struct Dyn; 2023 Jun; 41(9):4106-4123. PubMed ID: 35467486
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Rudrapal M; Issahaku AR; Agoni C; Bendale AR; Nagar A; Soliman MES; Lokwani D
    J Biomol Struct Dyn; 2022; 40(20):10437-10453. PubMed ID: 34182889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the dual effects of antiviral drugs on SARS-CoV-2 receptors and the ACE2 receptor using structure-based virtual screening and molecular dynamics simulation.
    Jahantigh HR; Ahmadi N; Shahbazi B; Lovreglio P; Habibi M; Stufano A; Gouklani H; Ahmadi K
    J Biomol Struct Dyn; 2023; 41(13):6051-6073. PubMed ID: 35876061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational approaches to define poncirin from
    Patil SM; Phanindra B; Shirahatti PS; Martiz RM; Sajal H; Babakr AT; Ramu R
    J Biomol Struct Dyn; 2023; 41(22):13078-13097. PubMed ID: 36695109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virtual screening of phytochemicals by targeting multiple proteins of severe acute respiratory syndrome coronavirus 2: Molecular docking and molecular dynamics simulation studies.
    Azeem M; Mustafa G; Mahrosh HS
    Int J Immunopathol Pharmacol; 2022; 36():3946320221142793. PubMed ID: 36442514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2.
    Islam R; Parves MR; Paul AS; Uddin N; Rahman MS; Mamun AA; Hossain MN; Ali MA; Halim MA
    J Biomol Struct Dyn; 2021 Jun; 39(9):3213-3224. PubMed ID: 32340562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the effects of chlorhexidine and several flavonoids as antiviral purposes on SARS-CoV-2 main protease: molecular docking, molecular dynamics simulation studies.
    Tatar G; Salmanli M; Dogru Y; Tuzuner T
    J Biomol Struct Dyn; 2022 Oct; 40(17):7656-7665. PubMed ID: 33749547
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Umadevi P; Manivannan S; Fayad AM; Shelvy S
    J Biomol Struct Dyn; 2022 Jul; 40(11):5053-5059. PubMed ID: 33372574
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of structural scaffold from interbioscreen (IBS) database to inhibit 3CLpro, PLpro, and RdRp of SARS-CoV-2 using molecular docking and dynamic simulation studies.
    Patil VR; Dhote AM; Patil R; Amnerkar ND; Lokwani DK; Ugale VG; Charbe NB; Firke SD; Chaudhari P; Shah SK; Mehta CH; Nayak UY; Khadse SC
    J Biomol Struct Dyn; 2023; 41(22):13168-13179. PubMed ID: 36757134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some
    Amin SA; Ghosh K; Gayen S; Jha T
    J Biomol Struct Dyn; 2021 Aug; 39(13):4764-4773. PubMed ID: 32568618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the interactions of HSA and SARS-CoV-2 papain-like protease against eugenol for novel COVID-19 drug discovery: spectroscopic and insilico study.
    Naz F; Khan I; Baammi S; Islam A
    J Biomol Struct Dyn; 2023 Nov; 41(19):10161-10170. PubMed ID: 36636828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-Silico approach for identification of effective and stable inhibitors for COVID-19 main protease (M
    Das P; Majumder R; Mandal M; Basak P
    J Biomol Struct Dyn; 2021 Oct; 39(16):6265-6280. PubMed ID: 32705952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reporting dinaciclib and theodrenaline as a multitargeted inhibitor against SARS-CoV-2: an
    Ahmad S; Pasha Km M; Raza K; Rafeeq MM; Habib AH; Eswaran M; Yadav MK
    J Biomol Struct Dyn; 2023 Jun; 41(9):4013-4023. PubMed ID: 35451934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening of potential bio-molecules from
    Mathpal S; Sharma P; Joshi T; Joshi T; Pande V; Chandra S
    J Biomol Struct Dyn; 2022; 40(20):9885-9896. PubMed ID: 34151733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.